ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
A periodic shareholding pattern filing for Zim Laboratories Ltd for the quarter ended March 31, 2026, disclosing promoter and public shareholding details.
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
Zim Laboratories Limited has announced the successful passing of Special Resolutions through a postal ballot, approving the remuneration structure for its Managing and Whole-Time Directors.
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.
Zim Laboratories Ltd reported revenue from operations of ₹94.2 Cr (+31.2% YoY) and a net loss of ₹4 Cr for Q1 FY27.
Zim Laboratories Limited has scheduled a board meeting for August 6, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Zim Laboratories allotted 1,09,451 equity shares under its ESOP scheme. Total paid-up capital increased to 5,36,58,488 shares.
Zim Laboratories allotted 1,09,451 equity shares under its ESOP/ESPS scheme. This increased the company's paid-up share capital to Rs 53.66 Crore.
ZIM Laboratories allotted 1,09,451 ESOP shares, realizing Rs.84.71 lakh (≈0.85 Crore). The allotment increases paid-up equity capital to Rs.53.66 Crore.
ZIM Laboratories issued a Postal Ballot notice to revise remuneration for its MD and Whole-Time Director. Total proposed annual compensation for both executives is Rs. 5.5 Crore.
ZIM Laboratories issued a Postal Ballot notice for shareholder approval of revised remuneration for its Managing Director and Whole-Time Director. Remote e-voting runs from July 13 to August 11.
Zim Laboratories held its 42nd Annual General Meeting on June 29, 2026. The proceedings included adoption of financial statements and director appointments.
Dr. Anwar Daud acquired 80,000 shares from Mr. Zulfiquar Kamal in an inter-se promoter transfer. This internal consolidation does not change overall promoter control.
ZIM Laboratories scheduled its 42nd Annual General Meeting for June 29, 2026. Key agenda items include adopting financial statements and re-appointing Executive Director Mr. Zulfiquar Kamal.
ZIM Laboratories released its FY 2025-26 Annual Report and 42nd AGM notice. The meeting is scheduled for June 29, 2026, via video conferencing.
ZIM Laboratories promoter Dr. Anwar Daud proposes to acquire 80,000 shares from another promoter via an inter-se transfer. The ₹0.69 Crore transaction maintains aggregate promoter control.
Zim Laboratories reported FY26 revenue of ₹3,744M, flat YoY, impacted by geopolitical issues in the MENA region and EU GMP constraints. Strategy focuses on remediation and transitioning from R&D to execution.
Zim Laboratories reported FY26 revenue of ₹3,744 Mn with 11.1% EBITDA margin. Strategy shifts towards innovative products (NIP/OTF) despite regulatory headwinds and geopolitical logistics challenges.
Zim Laboratories received Italian regulatory approval for its Dabigatran Etexilate capsules. This authorization facilitates market entry into Italy and potential expansion across Europe.
Zim Laboratories appointed M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27. This ensures regulatory compliance and oversight for the upcoming fiscal year.
Zim Laboratories Ltd reported revenue from operations of ₹105.3 Cr (-3.1% YoY) and net profit of ₹3.7 Cr (-24.5% YoY) for Q4 FY26.
Zim Laboratories reported annual consolidated total income of ₹385.78 Crore for FY26. The Board also appointed M/s Dhananjay V. Joshi & Associates as Cost Auditors.
Zim Laboratories scheduled a board meeting for May 19, 2026, to approve audited financial results. The trading window remains closed until May 21, 2026.
Zim Laboratories granted 1,29,200 stock options at Rs. 77.40 each, totaling ₹1.00 Crore. This employee incentive scheme supports long-term talent retention and alignment.
ZIM Laboratories completed an EU GMP inspection by German and Portuguese authorities at its Nagpur facility. No adverse observations were reported, maintaining regulatory compliance standards.
Zim Laboratories Limited has allotted 48,726 equity shares under its ESOP/ESPS scheme on April 18, 2026. This allotment increases the company's total paid-up share capital from ₹53.50 Crore to ₹53.55 Crore.